p40 / p63 delta Antibody

Biorbyt

p40 / p63 delta Antibody

16

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the p40 antibody to be titered up or down for optimal performance.1. Staining of FFPE tissues requires boiling sections in 1mM EDTA, pH 9, for 10-20 min followed by cooling at RT for 20 min.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT IHC-P, WB

Research Use Only

Polyclonal

Unconjugated

TP63

tumor protein p63

AIS; amplified in squamous cell carcinoma; B(p51A); B(p51B); chronic ulcerative stomatitis protein; EEC3; keratinocyte transcription factor KET; KET; LMS; NBP; OFC8; p40; p51; p53CP; p63; p73H; p73L; RHS; SHFM4; TP53CP; TP53L; TP73L; transformation-related protein 63; tumor protein 63; tumor protein p53-competing protein

Rabbit

IgG

p40 (p63 delta) is a marker recently determined to be highly specific for squamous basal cells in the immunohistochemistry (IHC) application. The current more routinely recommended marker, p63, appears to have less specificity compared to p40, especially on squamous cell tumors. The ability to differentiate between lung adenocarcinoma vs. squamous cell carcinoma is difficult and has bearing on the different therapeutic avenues for each subtype treatment. p40 antibodyi1/2s ability to distinguish between the tumor types appears to be superior when compared to p63. The ability to utilize a p40 antibody probe as a squamous cell marker bolsters its use for future sub-classification of lung cancers, especially by immunohistochemical techniques.

Human, Mouse, Rat

-20°C,2°C to 8°C

12352203